Priporočila za preprečevanje in zdravljenje slabosti in bruhanja ob sistemskem onkološkem zdravljenju
Slabost in bruhanje ostajata kljub velikemu napredku najpogostejša neželena učinka sistemskega zdravljenja, ki bistveno zmanjšata bolnikovo kvaliteto življenja in zmanjšata njegovo komplianco za nadaljevanje sistemskega zdravljenja. Priporočila za preprečevanje in zdravljenje slabosti in bruhanja zaradi zdravljenja s citostatiki so bila objavljena leta 2003 v reviji Onkologija. S tem prispevkom dopolnjujemo priporočila za obravnavo slabosti in bruhanja z novostmi, ki so bila objavljena v NCCN smernicah leta 2014 in MASCC in ESMO leta 2010 (1,2).
In spite of great advancement, nausea and vomiting remain the most common undesirable effects of systemic cancer treatment, which substantially lower the patients’ quality of life and reduce their compliance to continue systemic treatment. Recommendations for prevention and treatment of nausea and vomiting resulting from cytostatic treatment were published in 2003 in Oncology magazine. This article complements the recommendations for treatment of nausea and vomiting with new developments, which were published in the NCCN guidelines in 2014 and MASCC and ESMO in 2010 (1, 2). We present our method for treating dysphagia with the help of intraluminal oesophageal stents. In our practice, the intraluminal oesophageal stent has proven to be a very effective and the most patient-friendly method for optimal delivery of nutrients before and during neoadjuvant therapy. There are few complications, and insertions do not have a negative impact on the perioperative outcomes.
by Authors
2014
2018-08-31 13:37:30
1060
slabost, bruhanje, onkološki bolniki, sistemsko zdravljenje
Martina
Reberšek
70
Nežka
Hribernik
70
UDK
4
616-006
ISSN pri članku
9
1408-1741
URN
14
URN:NBN:SI:doc-QSP273HS
COBISS_ID
3
1964155
OceCobissID
13
65324032
RAZ_Rebersek_Martina_i2014.pdf
444086
Predstavitvena datoteka
2018-08-31 13:37:30